Only highest-dose iberdomide outperforms placebo in SLE; adverse events high - Healio

Iberdomide, a novel oral cereblon modulator, was superior to a placebo only in patients with systemic lupus erythematosus who received the highest dose in a phase 2 trial, albeit with a high incidence of adverse events, according to data.

Source/Disclosures Disclosures: This study was funded by Bristol Myers Squibb. Merrill reports consulting fees from AbbVie, Amgen, Astellas Pharma, AstraZeneca, Aurinia, Biogen, Bristol Myers Sq… [+7393 chars]

full article...